Table 5.

Characteristics of patients responding to the treatment

	Sex	Age	Diagnosis	Previous treatment	Dose level	No. of cycles	Response
1	M	49	Adenocarcinoma of the esophagus, liver mets	5-FU/cisplatin with XRT, Taxol	6/125 0/125	6 6	CR after 6 cycles, CA 19-9: 7,785 → 12.8 after 4 cycles, continued to be normal for 11 months
2	F	73	Inflammatory breast Ca, mets to chest wall	5-FU, AC, taxotere, navelbine, gemcitabine, xeloda, XRT	6/50	1	cPR of the chest wall lesions
3	F	53	Inflammatory breast Ca, mets to the chest wall	Neoadjuvant AC, adjuvant Taxotere	6/75	4	cPR of the chest wall lesions after 1 cycle
4	M	53	Adenocarcinoma of the esophagus, liver, retroperitoneal LN mets	5-FU/cisplatin with XRT	6/125	2	PR (55% reduction after 2 cycles)
5	M	71	Squamous ca of the esophagus, retroperitoneal LN mets	5-FU/cisplatin with XRT, taxotere	6/125 0/125	6 2	MR (39% reduction after 2 cycles), PR (58% reduction after 4 cycles), SD after 6 cycles
6	M	28	Gastric Ca, liver and lung mets	5FU/Leu, doxirubicin, Taxol, LY295501, Alimta, XRT	6/50 6/40	1 4	MR (25% reduction after 2 cycles)
7	M	52	Adenocarcinoma of the esophagus, lung and LN mets	5-FU/cisplatin, Taxol	6/75	6	MR (28% reduction of metastatic LNs)
					0/75	2	TTP = 32 weeks
8	F	56	Bronchioloalveolar Ca, lung mets	Taxotere/xeloda	6/75	4	MR (42% after 6 cycles)
					6/50	2
					0/50	2	TTP = 37 weeks
					0/75	1
9	M	80	Non-operable NSCLC, progression after XRT and 1st line chemo	XRT, Taxol	6/75 6/50	2 2	MR (27% reduction after 2 cycles)
10	M	43	NSCLC, liver mets	Taxol/carboplatin, gemcitabine/carboplatin	6/100	2	MR (Reduction in the lung mets)
				Taxotere/xeloda, XRT	6/75	2
11	M	49	Squamous Ca of the esophagus, recurrent bulky mediastinal LN	Neoadjuvant 5-FU/cisplatin with XRT	6/100	6	MR (28% reduction after 4 cycles) TTP 24 weeks
12	F	75	Gall bladder Ca, liver and LN mets	No	6/100	2	MR (36% reduction after 2 cycles)
13	F	67	Adenocarcinoma of unknown primary, favoring pancreas Ca, liver and lung mets	Cisplatin/gemcitabine	6/150	1	MR (Liver mets slightly decreased in size)
14	M	53	Gastric Ca liver mets	No	6/125	4	MR (27% reduction after 4 cycles)
15	F	51	Inflammatory breast Ca, recurrent chest wall lesion	CMF, Taxol	6/125/C	1	Clinical MR of the chest wall lesion
16	F	73	Pancreatic Ca, recurrence	Adjuvant 5-FU and XRT	6/100	1	CA 19-9: 865 → 172 after 1 cycle

AC doxorubicin, cytophosphamide, 5-FU 5-fluorouracil, Leu leucovorin, Taxol paclitaxel, LN lymph nodes, NSCLC non-small cell lung cancer, Met metastasis, CMF cytophosphamide, methotrexate, 5-fluorouracil, XRT external bean radiation treatment, Ca cancer, cPR clinical partial response, TTP total time to progression, MR minor response, C celecoxib